RxDoctor Payments Data

Qihua Fan, MD

Neurology · Henrico, VANPI 1467806687

Payments from drug & device makers

$39,166in general payments, 2019–2025

Across 71 payments — averaging $551.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$31K
  • Lexicon Pharmaceuticals, Inc.$3K
  • Argenx US, Inc.$2K
  • AstraZeneca$2K
  • Janssen Scientific Affairs, LLC$1K
  • UCB, Inc.$323
  • plus $478 from 3 others

What the payments were for

  • Consulting fees$2,9258%
  • Speaking & faculty fees$27,97476%
  • Travel & lodging$2,5627%
  • Food & beverage$2,9778%
  • Education$2001%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,166 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$52,616
Medicare patients
263
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WainuaEplontersen Sodium18$727,857
Radicava OrsEdaravone29$411,087
Pregabalin57$3,437
Riluzole25$2,639
Pyridostigmine Bromide27$2,238
Gabapentin110$1,743
Baclofen26$559
Duloxetine Hcl29$420
Tizanidine Hcl14$383
Amitriptyline Hcl17$294
Venlafaxine Hcl ErVenlafaxine Hcl29$211
Cyclobenzaprine Hcl23$171
Prednisone16$132
Sumatriptan Succinate11$58
Diclofenac Sodium13$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaWainua$1,612$727,85718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 neurology providers in Virginia.

Other neurology in Henrico

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →